8432 Stock Overview
Develops and markets pharmaceutical products in Taiwan and Asia. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
My Notes
Capture your thoughts, links and company narrative
TSH Biopharm Corporation Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$59.80 |
| 52 Week High | NT$71.10 |
| 52 Week Low | NT$49.10 |
| Beta | 0.21 |
| 1 Month Change | -1.97% |
| 3 Month Change | -8.56% |
| 1 Year Change | 19.12% |
| 3 Year Change | 42.04% |
| 5 Year Change | -23.92% |
| Change since IPO | 3.25% |
Recent News & Updates
Shareholder Returns
| 8432 | TW Pharmaceuticals | TW Market | |
|---|---|---|---|
| 7D | 1.0% | 0.5% | 3.5% |
| 1Y | 19.1% | 0.1% | 28.0% |
Return vs Industry: 8432 exceeded the TW Pharmaceuticals industry which returned 0.1% over the past year.
Return vs Market: 8432 underperformed the TW Market which returned 28% over the past year.
Price Volatility
| 8432 volatility | |
|---|---|
| 8432 Average Weekly Movement | 3.4% |
| Pharmaceuticals Industry Average Movement | 3.7% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in TW Market | 7.9% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 8432 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 8432's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | n/a | Sze-Yuan Yang | www.tshbiopharm.com |
TSH Biopharm Corporation Limited develops and markets pharmaceutical products in Taiwan and Asia. It offers products for cardiovascular, central nervous, gastrointestinal, and others. The company was founded in 1999 and is headquartered in Taipei city, Taiwan.
TSH Biopharm Corporation Limited Fundamentals Summary
| 8432 fundamental statistics | |
|---|---|
| Market cap | NT$2.27b |
| Earnings (TTM) | NT$119.68m |
| Revenue (TTM) | NT$1.05b |
19.2x
P/E Ratio2.2x
P/S RatioIs 8432 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 8432 income statement (TTM) | |
|---|---|
| Revenue | NT$1.05b |
| Cost of Revenue | NT$511.80m |
| Gross Profit | NT$539.18m |
| Other Expenses | NT$419.50m |
| Earnings | NT$119.68m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 3.12 |
| Gross Margin | 51.30% |
| Net Profit Margin | 11.39% |
| Debt/Equity Ratio | 0% |
How did 8432 perform over the long term?
See historical performance and comparisonDividends
2.1%
Current Dividend Yield41%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/21 12:21 |
| End of Day Share Price | 2025/01/21 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
TSH Biopharm Corporation Limited is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yi-hsin Lee | Jih Sun Securities Investment Consulting Co., Ltd. |
| Hsiu Chi Lin | Masterlink Securities Corp. |